Patients with refractory temporal lobe epilepsy (TLE) are commonly recruited for investigational anti-epileptic drug (XAED) studies. However, the long-term outcome of TLE after exposure to XAEDs is poorly documented. In this pilot study, we report the USC Epilepsy Center's experience of 19 patients with TLE enrolled in three XAED trials. The data reinforce that TLE is a drug-resistent epilepsy, and referral of good surgical candidates for surgery rather than XAED trials is more likely to result in remission.
INTRODUCTION
Only 20-40% of patients with medically refractory partial seizures have a greater than 50% reduction in seizures after exposure to an experimental anti-epileptic drug (XAED) ~-5. Fewer yet have a greater than 75% reduction in seizure frequency, and recent data indicates that remission is rare ~-s. Further, the longterm impact of XAEDs on temporal lobe epilepsy (TLE) is unknown because most studies report results for partial seizures rather than for TLE. In contrast to XAEDs, long-term efficacy of epilepsy surgery is established. The NIH consensus statement cites 5-year surgical remission rates of 55-75% for temporal lobectomies 7. Therefore, the low likelihood of remission from an XAED has significant implications for treatment decisions and XAED recruitment 7.s.
In order to begin to understand the efficacy of XAEDs in TLE, we report our centre's experience with three consecutive XAED trials.
METHODS
Since 1990, 27 patients with medically refractory seizures were enrolled in one of three experimental anti-epileptic drug trials at the University of Southern California Epilepsy Center. Twenty patients were identified who definitely met the criteria for TLE and 19 were actually exposed to XAEDs (one patient initially randomized to placebo never received a drug). The diagnosis of TLE was based on the proposed revised classification of epilepsies and epileptic syndromes of the International League Against Epilepsy 9. Included for analysis were patients with simple partial (autonomic, psychic, experiential auras or dysphasia) and/or complex partial seizures characterized by motor arrest, oral alimentary automatisms, followed by post-ictal confusion. Only patients with EEG abnormalities characteristic of TLE were included for analysis (exclusively temporal lobe spikes, temporal sharp waves or temporal slow waves).
All patients enrolled in experimental drug trials since 1990 were included. Two trials were randomized double-blind placebo controlled and one was open label. For the doubleblind studies, outcome was defined as the percent reduction from baseline in seizure frequency at completion of the double-blind treatment phase (3 or 4 months) and 3 or 6 months for the open label study (whichever was longest prior to discontinuation from the study).
Outcome was graded based on a scale similar to that used at our center to determine outcome after epilepsy surgery. Grade 1 was defined as greater than or equal to 75% reduction in seizure frequency from baseline, Grade 2 was defined as 50-74~ reduction, Grade 3 was defined as 25-49~ reduction, and Grade 4 was defined as 0-24~ reduction from baseline. Table 1 summarizes the response to an XAED in the 19 patients with TLE. Two patients (11%) were classified as Grade 1 (>75% reduction in seizures), of whom only one (5%) became seizure-free. Twelve patients (63%) were classified as Grade 4 (less than 25% reduction in seizures). The mean reduction in seizure frequency in the group was 17%. The mean response grade for the group was 3.3.
RESULTS
No life-threatening side effects were experienced after exposure to an XAED. Sixteen (84~} were discontinued from the XAED (three discontinued due to toxicity, one due to protocol violation, and 12 due to lack of efficacy). Three (16c~) continued the XAED in long-term follow-up.
Of the 16 patients who did not continue on a XAED, five underwent temporal lobectomy. All five had a minimum follow-up of 1 year, and all had a greater than 75~ reduction in seizures {Grade 1). Three of the four are seizure-free and one has had a greater than 90% reduction in seizures (aura only). Of those who did not undergo epilepsy surgery, five were under-insured, three were poor candidates due to psychiatric disorders or bitemporal epilepsy, and the rest were not interested in surgery due to fear of morbidity. Even if one excludes from analysis those three patients who were poor candidates, the difference in outcome between surgically treated and those who did not undergo surgery is significant (P = 0.01, Fisher Exact Test) ( Table 2 ). 
DISCUSSION
To our knowledge, this pilot study is the first to report the efficacy of XAEDs specifically in TLE. These data provide further evidence that though possible, it is highly unlikely that a patient with TLE will undergo remission after exposure to existing XAEDs. This result is similar to outcome studies of TLE after conventional therapy. this fact (Table 3) . Generally, only 20-45% will have greater than a 50% reduction in seizure frequency 1-5. In the two studies in which seizure-free data is available (vigabatrin and zonisamide), only 4-5% of a total of 257 patients became seizure-free 3'4.
In contrast, temporal lobectomy in medically refractory TLE is highly efficacious ~'s'12.
Ojemann's group reported that 60% of 92 patients with TLE had a greater than 75% reduction in seizures over a five-year period 12. Walczak et al. reported that 89 of 100 patients who underwent temporal lobectomy had a greater than 75% reduction in seizure frequency after at least 2 years, and 63% were seizure-free s . In our series of 19 patients, the difference in response to surgery compared to the XAED was significant. Only 2/19 exposed to the XAED had a greater than 75% reduction in seizures, vs 5/5 who underwent temporal lobectomy. However, not all patients in XAED trials with TLE are good surgical candidates. Those who go to epilepsy surgery most likely represent a select group. Also, many patients with TLE are enrolled in XAED trials precisely because they are not good surgical candidates, as was the case with three of our patients. In our series, however, 5/11 XAED failures did not undergo surgery due to underinsurance, suggesting that under-insurance and the high cost of epilepsy surgery is one of several reasons for enrolment in an XAED trial. Further study of this issue in larger numbers is needed, and we are in the process of pooling data from multiple centres to assess the response to epilepsy surgery in those who fail XAED trials.
Clearly, XAED studies play a critical role in the development of new drugs, which are obviously needed. However, the data from this study and from Table 3 should instil caution when enroling patients in XAED studies who are good surgical candidates. Further, enrolment of patients with TLE, which is a highly drug-resistant epilepsy, may obscure and confound the efficacy of otherwise effective XAEDs, which might be effective in other epilepsies. As for informed consent, patients with TLE who are good surgical candidates should be informed that epilepsy surgery, though costly and with its own risks, is an accepted alternative treatment with long-term remission rates of 50-60%. Further, patients should be informed that XAEDs may result in significant improvement, but less commonly in complete remission.
